Scientists test First-of-its-Kind vaccine aimed at multiple coronaviruses
NCT ID NCT06950177
Summary
This is an early-stage study testing the safety and immune response of a new vaccine designed to protect against multiple coronaviruses, including COVID-19 variants and potential future threats. The study will enroll 51 healthy adults to receive two doses of the experimental vaccine at different strength levels. Researchers will monitor for side effects and check if the vaccine triggers a broad protective immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS COV 2 INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University Health System
Durham, North Carolina, 27709, United States
Conditions
Explore the condition pages connected to this study.